Shoshana G. Marvin

Shoshana G. Marvin is counsel in Sterne Kessler’s Biotechnology & Chemical Practice Group. Shoshana’s practice focuses on the preparation and prosecution of U.S. and foreign patent applications, as well as the preparation of opinions of counsel. She has drafted numerous invalidity,
noninfringement, freedom-to-operate, and patentability opinions for pharmaceutical patents, including patents that claim active pharmaceutical ingredients, polymorphs, chemical synthesis, pharmaceutical formulations, and methods of treatment. Shoshana has also prepared and prosecuted patents relating to a wide variety of technologies including molecular biology, cancer biology, therapeutic antibodies, virology, and vaccines.

Shoshana’s Master’s level graduate research focused on identifying enzyme targets for prostate cancer prevention at the Illinois Institute of Technology, under the direction of Dr. David McCormick.

Prior to joining Sterne Kessler, Shoshana worked at an intellectual property law firm in Washington, D.C. preparing and prosecuting patent applications for U.S. and international clients.

Shoshana earned her J.D. from the George Washington University Law School, her M.S. in biology with a concentration in biotechnology from the Illinois Institute of Technology, and her B.S. in biological sciences with a specialization in biotechnology from Florida Atlantic University.

Technical Publications

• Baltatzis, A and Marvin, S. (January 2014). “Recent Pharmaceutical Patent Decisions in the United States,” Journal of Intellectual Property Rights (JIPR), Vol. 19.
• Fanelli, D and Marvin, S. (June 24, 2010). “The Future Of Biosimilars In Health Care And Litigation,” Law360.
• Fanelli, D and Marvin, S. (April 9, 2010). “Time Is Money: Federal Circuit Affirms Wyeth,” IPO.